iBio, Inc. shares rise 60.11% after-hours following promising antibody data and upcoming conference call.

Ibio, Inc. surged 60.11% in after-hours trading, with the company announcing promising data for its Myostatin and Activin E antibody treatments and plans to reveal a third target in its AstralBio Collaboration. The company will host a conference call on June 24 to discuss these advancements, which are expected to drive further growth in the obesity and cardiometabolic disease treatment markets.